Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 4/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.42 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25370544 | 0.84 | LGMN (0.54) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1599425 | 0.83 | PRKDC (0.61) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5063509 | 0.83 | PRKDC (0.58) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2475418 | 0.83 | PRKDC (0.58) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4429989 | 0.82 | SIRT6 (0.52) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL11061693 | 0.81 | PRKDC (0.58) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL7161474 | 0.80 | PRKDC (0.55) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1701348 | 0.79 | PIK3CD (0.51) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1600364 | 0.79 | PRKDC (0.54) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL7138533 | 0.78 | PRKDC (0.63) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497614-B2 | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4263829-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | Vertex Pharmaceuticals Incorporated (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230022146-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-26 | — | — | US | disclosed |
| US-20220228142-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | VERTEX PHARMACEUTICALS INCORPORATED | 2022-07-21 | — | — | US | disclosed |
| WO-2022133246-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-3983542-A2 | METHODS AND COMPOSITIONS FOR IMPROVED HOMOLOGY DIRECTED REPAIR | CRISPR Therapeutics AG (CH) | 2022-04-20 | — | — | EP | disclosed |
| EP-3983545-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | Vertex Pharmaceuticals Incorporated (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022010991-A1 | COMPOSITIONS AND METHODS FOR INCREASING HOMOLOGY-DIRECTED REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20210008161-A1 | METHODS AND COMPOSITIONS FOR IMPROVED HOMOLOGY DIRECTED REPAIR | CRISPR THERAPEUTICS AG (CH) | 2021-01-14 | — | — | US | disclosed |
| WO-2020257325-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | VERTEX PHARMACEUTICALS INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254872-A2 | METHODS AND COMPOSITIONS FOR IMPROVED HOMOLOGY DIRECTED REPAIR | CRISPR THERAPEUTICS AG (CH) | 2020-12-24 | — | — | WO | disclosed |
| WO-2014130922-A1 | COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2014-08-28 | — | — | WO | disclosed |
| EP-2519824-A1 | PI3K MODULATORS, RHO KINASE MODULATORS AND METHODS OF IDENTIFYING AND USING SAME | Corning Incorporated (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011081968-A1 | PI3K MODULATORS, RHO KINASE MODULATORS AND METHODS OF IDENTIFYING AND USING SAME | CORNING INCORPORATED (US) | 2011-07-07 | — | — | WO | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220228142-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | HBB, HBG1, HBG2 | PRKDC 417/4885PIK3CD 3390/4885PIK3CA 3547/4885 |
| US-20230022146-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | HBB, HBG1, HBG2 | PRKDC 417/4885PIK3CD 3457/4885PIK3CA 3697/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | PRKDC 17/4885PIK3CD 829/4885PIK3CA 454/4885 |
| US-12497614-B2 | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies | HBB, HBG1, HBG2 | PRKDC 417/4885PIK3CD 3390/4885PIK3CA 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.